An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Rucaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms AME
- Sponsors Clovis Oncology
- 20 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 12 Dec 2016 New trial record